Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Devis, G.
Right arrow Articles by Malaisse, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Devis, G.
Right arrow Articles by Malaisse, W. J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 24, Issue 6 247-251, Copyright © 1975 by American Diabetes Association

ARTICLES

Calcium antagonists and islet function. I. Inhibition of insulin release by verapamil

G Devis, G Somers, E Van Obberghen and WJ Malaisse

Verapamil is a potent calcium antagonist known to inhibit excitation-contraction coupling in both myocardium and myometrium. Its effect upon glucose- and sulfonylurea-induced insulin release was investigated in the isolated perfused rat pancreas. After twenty-five minutes' pretreatment and at concentrations ranging between 0.8 and 8.1 muM, verapamil caused a dose-related inhibition of glucose-induced insulin release during both the early and late phase of the secretory process. At a concentration of 0.8 muM, the degree of inhibition was more marked when the exposure time to verapamil prior to stimulation with glucose was increased to sixty minutes. Verapamil also inhibited gliclazide-induced insulin release. Infusion of verapamil during the late phase of the secretory response to glucose demonstrated that the inhibition of insulin release was an immediate and reversible phenomenon. The inhibitory effect of verapamil was enhanced at a subnormal calcium concentration and reduced at a high calcium concentration. These findings are consistent with the well-known calcium dependency of both glucose- and sulfonylurea-induced insulin release and suggest that verapamil might be a promising tool for further studies on the interactions between cations and secretagogues in the beta-cell secretory process.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
N. S. Harris
Case 24-2006 -- A 40-Year-Old Woman with Hypotension after an Overdose of Amlodipine
N. Engl. J. Med., August 10, 2006; 355(6): 602 - 611.
[Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Liu, N. Hilliard, and G. H. Hockerman
Cav1.3 Is Preferentially Coupled to Glucose-Induced [Ca2+]i Oscillations in the Pancreatic {beta} Cell Line INS-1
Mol. Pharmacol., May 1, 2004; 65(5): 1269 - 1277.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Liu, N. Dilmac, N. Hilliard, and G. H. Hockerman
Cav1.3 Is Preferentially Coupled to Glucose-Stimulated Insulin Secretion in the Pancreatic beta -Cell Line INS-1
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 271 - 278.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
Y. Tsubamoto, K. Eto, M. Noda, S. Daniel, S. Suga, S. Yamashita, H. Kasai, M. Wakui, G. W. G. Sharp, S. Kimura, et al.
Hexamminecobalt(III) Chloride Inhibits Glucose-induced Insulin Secretion at the Exocytotic Process
J. Biol. Chem., January 26, 2001; 276(5): 2979 - 2985.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1975 by the American Diabetes Association.